Screening protein isoforms predictive for cancer using immunoaffinity capture and fast LC-MS in PRM mode

Proteomics - Clinical Applications

Volumn 9, Issue 7-8, 2015, Pages 695-705

  Lesur, Antoine ^a   Ancheva, Lina ^a   Kim, Yeoun Jin ^a   Berchem, Guy ^a,b   van Oostrum, Jan ^a   Domon, Bruno ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b Centre Hospitalier of Luxembourg   (Luxembourg)

Author keywords

EGFR; Fast LC; KRas; PLASMA; PRM; SAA

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; RAS PROTEIN; ISOPROTEIN; PEPTIDE; TUMOR PROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER RESEARCH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; GENETIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOAFFINITY CAPTURE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; PARALLEL REACTION MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; NEOPLASM; PROCEDURES; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; PROTEIN ISOFORMS; RAS PROTEINS; SEQUENCE ALIGNMENT;

EID: 84940830035     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400158     Document Type: Article

References (28)

1. Croce, C. M., Oncogenes and cancer. N. Engl. J. Med. 2008, 358, 502-511.
2. Stratton, M. R., Campbell, P. J., Futreal, P. A., The cancer genome. Nature 2009, 458, 719-724.
3. Bozic, I., Antal, T., Ohtsuki, H., Carter, H. et al., Accumulation of driver and passenger mutations during tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 18545-18550.
4. Chiosea, S. I., Sherer, C. K., Jelic, T., Dacic, S., KRAS mutant allele-specific imbalance in lung adenocarcinoma. Modern Pathol. 2011, 24, 1571-1577.
5. Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H. et al., Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PloS One 2009, 4, e7464.
6. Sondergaard, J. N., Nazarian, R., Wang, Q., Guo, D. et al., Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J. Transl. Med. 2010, 8, 39.
7. Brambilla, E., Gazdar, A., Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur. Respir. J. 2009, 33, 1485-1497.
8. Pao, W., Girard, N., New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011, 12, 175-180.
9. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C. et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
10. Pao, W., Miller, V., Zakowski, M., Doherty, J. et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101, 13306-13311.
11. Levy, M. A., Lovly, C. M., Pao, W., Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res. 2012, 22, 2101-2108.
12. Ruppen-Canas, I., Lopez-Casas, P. P., Garcia, F., Ximenez-Embun, P. et al., An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. Proteomics 2012, 12, 1319-1327.
13. Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J. et al., Mutant proteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. USA 2011, 108, 2444-2449.
14. Halvey, P. J., Ferrone, C. R., Liebler, D. C., GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J. Proteome Res. 2012, 11, 3908-3913.
15. Sherrod, S. D., Myers, M. V., Li, M., Myers, J. S. et al., Label-free quantitation of protein modifications by pseudo selected reaction monitoring with internal reference peptides. J. Proteome Res. 2012, 11, 3467-3479.
16. Suda, K., Tomizawa, K., Mitsudomi, T., Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010, 29, 49-60.
17. Mitsudomi, T., Yatabe, Y., Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010, 277, 301-308.
18. Guo, X., Trudgian, D. C., Lemoff, A., Yadavalli, S., Mirzaei, H., Confetti: a multiprotease map of the HeLa proteome for comprehensive proteomics. Mol. Cell. Proteomics 2014, 13, 1573-1584.
19. Gupta, N., Hixson, K. K., Culley, D. E., Smith, R. D., Pevzner, P. A., Analyzing protease specificity and detecting in vivo proteolytic events using tandem mass spectrometry. Proteomics 2010, 10, 2833-2844.
20. Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E. et al., Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Investig. 2006, 116, 2695-2706.
21. Paret, C., Schon, Z., Szponar, A., Kovacs, G., Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur. Urol. 2010, 57, 859-866.
22. Mattarollo, S. R., Smyth, M. J., A novel axis of innate immunity in cancer. Nat. Immunol. 2010, 11, 981-982.
23. Indovina, P., Marcelli, E., Maranta, P., Tarro, G., Lung cancer proteomics: recent advances in biomarker discovery. Int. J. Proteomics 2011, 2011, 726-869.
24. Sung, H. J., Ahn, J. M., Yoon, Y. H., Rhim, T. Y. et al., Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J. Proteome Res. 2011, 10, 1383-1395.
25. Booth, D. R., Booth, S. E., Gillmore, J. D., Hawkins, P. N., Pepys, M. B., SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998, 5, 262-265.
26. Nelson, R. W., Krone, J. R., Bieber, A. L., Williams, P., Mass spectrometric immunoassay. Anal. Chem. 1995, 67, 1153-1158.
27. Peterman, S., Niederkofler, E. E., Phillips, D. A., Krastins, B. et al., An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA-HR/AM). Proteomics 2014, 14, 1445-1456.
28. Lesur, A., Varesio, E., Hopfgartner, G., Accelerated tryptic digestion for the analysis of biopharmaceutical monoclonal antibodies in plasma by liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. A 2010, 1217, 57-64.